Request Copyright Permission

Carbon Neutral: TRELEGY ELLIPTA From Concept to Delivery

Henderson RK, Whelan GS, Field D, Davidson G, Cheli A, Usai G, Dowling L.

Respiratory Drug Delivery 2022. Volume , 2022: 163-174.

Abstract:

Climate change and nature loss are impacting the world and human health. Healthcare systems and pharmaceutical companies have set ambitious targets to have net zero impact on climate. While reducing carbon emissions is the primary focus of companies and organizations, there is also a role for using carbon credits to offset the carbon emissions that cannot be abated. To learn how the carbon offset market works, GlaxoSmithKline (GSK) made TRELEGY ELLIPTA carbon neutral in the United Kingdom (UK) in 2021 through a certification process assured by the Carbon Trust. GSK measured and certified the product carbon footprint of TRELEGY ELLIPTA, developed and began to implement a carbon reduction plan, then invested in a forest restoration project in Ghana in order to purchase and retire sufficient carbon credits to offset the carbon footprint of TRELEGY ELLIPTA in the UK. This paper will cover the process and learnings from bringing GSK’s first carbon neutral medicine to the UK market on World COPD Day, November 17, 2021.